Abbott (NYSE: ABT) reported AACR 2026 data showing its Cancerguard multi-cancer early detection test uses a multi-biomarker methylation-plus-protein approach to improve detection across stages. In a case-control study, signals were 47.1% methylation-only, 7.4% protein-only, 45.5% combined; false positives were 2.6% and none were positive for both markers. The AACR award noted DETECT-A multiyear outcomes with ~4-year median follow-up, where treated stage I–II patients remained alive and cancer-free.
Friday, April 17, 2026
Abbott: New data at AACR sets advancements in Cancerguard® Multi-Cancer Early Detection Test
Abbott (NYSE: ABT) reported AACR 2026 data showing its Cancerguard multi-cancer early detection test uses a multi-biomarker methylation-plus-protein approach to improve detection across stages. In a case-control study, signals were 47.1% methylation-only, 7.4% protein-only, 45.5% combined; false positives were 2.6% and none were positive for both markers. The AACR award noted DETECT-A multiyear outcomes with ~4-year median follow-up, where treated stage I–II patients remained alive and cancer-free.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.